MediWoundMDWD +2.19%56 FCF Margin % is -581.29% as of Mar. 2026. GuruFocus rates MDWD with a GF Score™ of 56/100 and a GF Value™ of $12.44 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 949 Biotechnology companies, MediWound ranks worse than 59.11% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MediWound's Free Cash Flow for the
three
months ended in Mar. 2026 was $-8.57 Mil. MediWound's Revenue for the
three
months ended in Mar. 2026 was $1.48 Mil. Therefore, MediWound's FCF Margin % for the quarter that ended in Mar. 2026 was -581.29%.
The historical rank and industry rank for MediWound's FCF Margin % or its related term are showing as below:
MDWD'
s FCF Margin % Range Over the Past 10 Years
Min: -1100.51 Med: -94.5 Max: 23.58
Current: -173.57
During the past 13 years, the highest FCF Margin % of MediWound was 23.58%. The lowest was -1100.51%. And the median was -94.50%.
MDWD's FCF Margin % is ranked worse than 59.11% of 949
companies
in the Biotechnology industry
Industry Median: -82.65
vs MDWD: -173.57
MediWound FCF Margin % Related Terms
MediWound FCF Margin % Historical Data
* Premium members only.
The historical data trend for MediWound's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MediWound's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediWound FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediWound's FCF Margin % distribution charts can be found below:
* The bar in red indicates where MediWound's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediWound (MDWD) has a FCF Margin % of -581.29% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MediWound and its competitors. According to the industry distribution chart, MediWound ranks #561 out of 949 companies in the Biotechnology industry, placing it in the top 59.1%.
Is MediWound's FCF Margin % too high?
MediWound's current FCF Margin % is -581.29%. Based on the distribution chart, MediWound ranks #561 out of 949 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MediWound has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's FCF Margin % compare to UNCY and ARCT?
According to the Biotechnology industry distribution chart, MediWound ranks #561 out of 949 companies for FCF Margin %. This places MediWound in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MediWound and its competitors. MediWound's current FCF Margin % is -581.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.44, compared to a current price of $15.16 — trading 21.9% above its estimated fair value. The current FCF Margin % is -581.29%. MediWound's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For MediWound (MDWD), the current FCF Margin % is -581.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediWound (MDWD) Overvalued in 2026?
Based on GuruFocus' analysis, MediWound stock appears to be overvalued.
The current stock price of $15.16 is trading 21.9% above its estimated GF Value™ of $12.44.
GuruFocus considers MediWound to be Modestly Overvalued.
Key valuation signals for MDWD:
FCF Margin %: -581.29%
GF Value™: $12.44 vs. price of $15.16 (21.9% above fair value)
No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score
Get the complete analysis for MDWD
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDWD has been successfully added to your 
